[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse MDM2

Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus, nucleoplasm. Cytoplasm. Nucleus, nucleolus. Note=Expressed predominantly in the nucleoplasm. Interaction with ARF(P14) results in the localization of both proteins to the nucleolus. The nucleolar localization signals in both ARF(P14) and MDM2 may be necessary to allow efficient nucleolar localization of both proteins. Colocalizes with RASSF1 isoform A in the nucleus.
Domain PF02201 SWIB/MDM2 domain
PF00641 Zn-finger in Ran binding protein and others
Function

E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation (PubMed:12821780, PubMed:15053880, PubMed:15195100, PubMed:15632057, PubMed:16337594, PubMed:17290220, PubMed:19098711, PubMed:19219073, PubMed:19837670, PubMed:19965871, PubMed:20173098, PubMed:20385133, PubMed:20858735, PubMed:22128911). Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells (By similarity). Ubiquitinates DLG4, leading to proteasomal degradation of DLG4 which is required for AMPA receptor endocytosis (By similarity).

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000302 response to reactive oxygen species
GO:0001666 response to hypoxia
GO:0001974 blood vessel remodeling
GO:0002027 regulation of heart rate
GO:0003007 heart morphogenesis
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0003170 heart valve development
GO:0003171 atrioventricular valve development
GO:0003179 heart valve morphogenesis
GO:0003181 atrioventricular valve morphogenesis
GO:0003197 endocardial cushion development
GO:0003203 endocardial cushion morphogenesis
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003230 cardiac atrium development
GO:0003231 cardiac ventricle development
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0003283 atrial septum development
GO:0006611 protein export from nucleus
GO:0006913 nucleocytoplasmic transport
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0006979 response to oxidative stress
GO:0007050 cell cycle arrest
GO:0007089 traversing start control point of mitotic cell cycle
GO:0007093 mitotic cell cycle checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0007507 heart development
GO:0007584 response to nutrient
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009636 response to toxic substance
GO:0009743 response to carbohydrate
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010039 response to iron ion
GO:0010225 response to UV-C
GO:0010266 response to vitamin B1
GO:0010466 negative regulation of peptidase activity
GO:0010498 proteasomal protein catabolic process
GO:0010721 negative regulation of cell development
GO:0010948 negative regulation of cell cycle process
GO:0010951 negative regulation of endopeptidase activity
GO:0010955 negative regulation of protein processing
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0014072 response to isoquinoline alkaloid
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014911 positive regulation of smooth muscle cell migration
GO:0016485 protein processing
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0030335 positive regulation of cell migration
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031345 negative regulation of cell projection organization
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0031647 regulation of protein stability
GO:0031648 protein destabilization
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0031670 cellular response to nutrient
GO:0032026 response to magnesium ion
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032434 regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process
GO:0033002 muscle cell proliferation
GO:0033157 regulation of intracellular protein transport
GO:0033273 response to vitamin
GO:0034504 protein localization to nucleus
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0034644 cellular response to UV
GO:0035902 response to immobilization stress
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0040017 positive regulation of locomotion
GO:0042176 regulation of protein catabolic process
GO:0042220 response to cocaine
GO:0042493 response to drug
GO:0042542 response to hydrogen peroxide
GO:0042770 signal transduction in response to DNA damage
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043278 response to morphine
GO:0043279 response to alkaloid
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043434 response to peptide hormone
GO:0043516 regulation of DNA damage response, signal transduction by p53 class mediator
GO:0043518 negative regulation of DNA damage response, signal transduction by p53 class mediator
GO:0043627 response to estrogen
GO:0044057 regulation of system process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044843 cell cycle G1/S phase transition
GO:0045472 response to ether
GO:0045665 negative regulation of neuron differentiation
GO:0045732 positive regulation of protein catabolic process
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045861 negative regulation of proteolysis
GO:0045862 positive regulation of proteolysis
GO:0045930 negative regulation of mitotic cell cycle
GO:0045931 positive regulation of mitotic cell cycle
GO:0046677 response to antibiotic
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0046825 regulation of protein export from nucleus
GO:0046827 positive regulation of protein export from nucleus
GO:0048545 response to steroid hormone
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048771 tissue remodeling
GO:0050768 negative regulation of neurogenesis
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051222 positive regulation of protein transport
GO:0051272 positive regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0051604 protein maturation
GO:0051961 negative regulation of nervous system development
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060047 heart contraction
GO:0060411 cardiac septum morphogenesis
GO:0060485 mesenchyme development
GO:0061136 regulation of proteasomal protein catabolic process
GO:0070301 cellular response to hydrogen peroxide
GO:0070482 response to oxygen levels
GO:0070613 regulation of protein processing
GO:0071156 regulation of cell cycle arrest
GO:0071157 negative regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0071214 cellular response to abiotic stimulus
GO:0071236 cellular response to antibiotic
GO:0071295 cellular response to vitamin
GO:0071301 cellular response to vitamin B1
GO:0071312 cellular response to alkaloid
GO:0071375 cellular response to peptide hormone stimulus
GO:0071391 cellular response to estrogen stimulus
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071478 cellular response to radiation
GO:0071482 cellular response to light stimulus
GO:0071494 cellular response to UV-C
GO:0071496 cellular response to external stimulus
GO:0072132 mesenchyme morphogenesis
GO:0072331 signal transduction by p53 class mediator
GO:0072395 signal transduction involved in cell cycle checkpoint
GO:0072401 signal transduction involved in DNA integrity checkpoint
GO:0072413 signal transduction involved in mitotic cell cycle checkpoint
GO:0072422 signal transduction involved in DNA damage checkpoint
GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint
GO:0090068 positive regulation of cell cycle process
GO:0090316 positive regulation of intracellular protein transport
GO:1900087 positive regulation of G1/S transition of mitotic cell cycle
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901797 negative regulation of signal transduction by p53 class mediator
GO:1901800 positive regulation of proteasomal protein catabolic process
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901989 positive regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1901992 positive regulation of mitotic cell cycle phase transition
GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint
GO:1902402 signal transduction involved in mitotic DNA damage checkpoint
GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint
GO:1902532 negative regulation of intracellular signal transduction
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1902808 positive regulation of cell cycle G1/S phase transition
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903052 positive regulation of proteolysis involved in cellular protein catabolic process
GO:1903317 regulation of protein maturation
GO:1903318 negative regulation of protein maturation
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1903522 regulation of blood circulation
GO:1903829 positive regulation of cellular protein localization
GO:1904705 regulation of vascular smooth muscle cell proliferation
GO:1904707 positive regulation of vascular smooth muscle cell proliferation
GO:1904738 vascular associated smooth muscle cell migration
GO:1904752 regulation of vascular associated smooth muscle cell migration
GO:1904754 positive regulation of vascular associated smooth muscle cell migration
GO:1904951 positive regulation of establishment of protein localization
GO:1990267 response to transition metal nanoparticle
GO:1990785 response to water-immersion restraint stress
GO:1990874 vascular smooth muscle cell proliferation
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
GO:2000147 positive regulation of cell motility
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
Molecular Function GO:0002039 p53 binding
GO:0004842 ubiquitin-protein transferase activity
GO:0016874 ligase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0019789 SUMO transferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0042975 peroxisome proliferator activated receptor binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0061630 ubiquitin protein ligase activity
GO:0061659 ubiquitin-like protein ligase activity
GO:0097110 scaffold protein binding
Cellular Component GO:0016604 nuclear body
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
> KEGG and Reactome Pathway
 
KEGG hsa04068 FoxO signaling pathway
hsa04110 Cell cycle
hsa04115 p53 signaling pathway
hsa04120 Ubiquitin mediated proteolysis
hsa04144 Endocytosis
hsa04151 PI3K-Akt signaling pathway
hsa04919 Thyroid hormone signaling pathway
Reactome R-HSA-198323: AKT phosphorylates targets in the cytosol
R-HSA-1280218: Adaptive Immune System
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-5674400: Constitutive Signaling by AKT1 E17K in Cancer
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-5688426: Deubiquitination
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-69615: G1/S DNA Damage Checkpoints
R-HSA-180292: GAB1 signalosome
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-2559585: Oncogene Induced Senescence
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-597592: Post-translational protein modification
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804760: Regulation of TP53 Activity through Methylation
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-6804757: Regulation of TP53 Degradation
R-HSA-6806003: Regulation of TP53 Expression and Degradation
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-3232118: SUMOylation of transcription factors
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-69541: Stabilization of p53
R-HSA-399719: Trafficking of AMPA receptors
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-5689880: Ub-specific processing proteases
R-HSA-69563: p53-Dependent G1 DNA Damage Response
R-HSA-69580: p53-Dependent G1/S DNA damage checkpoint
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MDM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MDM2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25398437MelanomaInhibit immunityHere we show how combining a senescence-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 in senescent tumors harboring wildtype 53. In the model studied, this effect is accompanied proliferation arrest, mitochondrial depolarization, apoptosis and immune clearance of cancer cells by antitumor leukocytes in a manner reliant upon CCL5, CCL1 and CXCL9.
24777531Melanoma; Colon CarcinomaInhibit immunity (T cell function)Here we identified the DUB USP15 as a crucial negative regulator of T cell activation. USP15 stabilized the E3 ubiquitin ligase MDM2, which in turn negatively regulated T cell activation by targeting the degradation of the transcription factor NFATc2. USP15 deficiency promoted T cell activation in vitro and enhanced T cell responses to bacterial infection and tumor challenge in vivo. USP15 also stabilized MDM2 in cancer cells and regulated p53 function and cancer-cell survival.
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MDM2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MDM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.180.708
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9080.647
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.360.824
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1860.662
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1920.931
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1730.953
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1630.738
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0520.98
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2950.896
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5460.766
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1720.953
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2430.156
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MDM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MDM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MDM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MDM2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MDM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MDM2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MDM2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMDM2
NameMDM2 proto-oncogene, E3 ubiquitin protein ligase
Aliases HDM2; MGC5370; mouse double minute 2, human homolog of; p53-binding protein; Mdm2, transformed 3T3 cell doub ......
Chromosomal Location12q13-q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MDM2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MDM2.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB02872Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]MethanoneSmall MoleculeMDM21
DB04144Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-MethanoneSmall MoleculeMDM21